{"id":"NCT01235975","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years","officialTitle":"Phase IIIb Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Meningococcal Vaccine [GSK 134612] When Given as One Dose to Healthy Subjects Aged 56 Years or Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11-30","primaryCompletion":"2011-07-29","completion":"2011-08-03","firstPosted":"2010-11-08","resultsPosted":"2017-04-28","lastUpdate":"2018-08-20"},"enrollment":400,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Meningococcal"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal vaccine GSK 134612","otherNames":[]},{"type":"BIOLOGICAL","name":"MencevaxACWY TM","otherNames":[]}],"arms":[{"label":"Group A","type":"EXPERIMENTAL"},{"label":"Group B","type":"ACTIVE_COMPARATOR"}],"summary":"This study evaluates the immunogenicity and safety of the meningococcal conjugate vaccine GSK 134612 given as single dose to healthy adults 56 years or older compared to the meningococcal polysaccharide vaccine MencevaxACWYTM.","primaryOutcome":{"measure":"Vaccine Response to Meningococcal Antigens (MenA, MenC, MenW-135 and MenY)","timeFrame":"One month after vaccination (Month 1)","effectByArm":[{"arm":"Nimenrix Group","deltaMin":134,"sd":null},{"arm":"Mencevax Group","deltaMin":55,"sd":null}],"pValues":[]},"eligibility":{"minAge":"56 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":19},"locations":{"siteCount":1,"countries":["Lebanon"]},"refs":{"pmids":["23494214"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":274},"commonTop":[]}}